Biomolecules & Therapeutics 2024; 32(2): 262-265  https://doi.org/10.4062/biomolther.2024.001
Erratum to "Small Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Fusion by Targeting Cavities on Heptad Repeat Trimers" [Biomol Ther 28(4), 311-319 (2020)]
Mahmoud Kandeel1,2,*, Mizuki Yamamoto3,4, Abdulla Al-Taher1, Aya Watanabe4, Kentaro Oh-hashi5, Byoung Kwon Park6, Hyung-Joo Kwon6,*, Jun-ichiro Inoue3,4 and Mohammed Al-Nazawi1
1Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia
2Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
3Research Center for Asian Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639,
4Division of Cellular and Molecular Biology, Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639,
5Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University, Gifu 501-1193, Japan
6Department of Microbiology, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
*E-mail: mkandeel@kfu.edu.sa (Kandeel M), hjookwon@hallym.ac.kr (Kwon HJ)
Tel: +966-568918734 (Kandeel M), +82-33-248-2635 (Kwon HJ)
Fax: +966-13-589-6617 (Kandeel M), +82-33-241-3640 (Kwon HJ)
Published online: March 1, 2024.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Body

The authors request to correct the plaque photos in Fig. 3A on page 317, Table 1 on page 314-316 and the 1st-6th line of left column of Results section on page 317. The authors conducted multiple experiments simultaneously to examine the effects of different treatments on MERS-CoV. During the manuscript preparation, the exact images of PBS and DMSO controls were unintentionally misused. As the overall patterns of plaque formation in the original figure and the revised one are similar, this error does not affect the conclusion of the article. However, the authors apologize for this accidental error and inconvenience.

Figure 3. (A) Screening of the inhibitors against MERS-CoV infection. The plaque formation assay was performed with 15 compounds. Prior to MERS-CoV infection, MERS-CoV was incubated with each compound (10 μM) for 30 min at 37°C and then added to Vero cells to infect with MERS-CoV. After 4 days of incubation in DMEM/F12 containing 0.6% oxoid agar, the plaques were observed by staining with crystal violet and then counted.

Table 1 Chemical structure of compounds and their inhibitory properties on MERS-CoV shown in Fig. 3A using plaques inhibition assay. The cytotoxicity values represent the average from three different cultures. Cell viability measurement was based on mitochondrial activity

Compound noIDChemical nameTotal plaque No.% PlaqueCytotoxicity against HEK cells
PBS496117.4
10% DMSO422100
2224071746
{4-[(1-{[3-(4-fluorophenyl)-1H-pyrazol-5-yl]carbonyl}pyrrolidin-3-yl)methyl]phenyl}methanol
26863.50.596
74F2282-0127*
1-(4-chlorophenyl)-N-(2-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)ethyl)-5-oxopyrrolidine-3-carboxamide
17240.80.568
7398931397
4-[3-({4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl}carbonyl)-1-piperidinyl]-2-(3-thienylmethyl)-1H-isoindole-1,3(2H)-dione
21250.20.602
75F2282-0124*
N-(2-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)ethyl)-5-oxo-1-(p-tolyl)pyrrolidine-3-carboxamide
33278.70.604
46505627
4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-2-naphthylbutanamide
31674.90.603
76F2282-0128*
N-(2-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)ethyl)-1-(3,4-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide
27665.40.520
5857295921
3-{[4-(2-{4-[(4-benzyl-1-piperidinyl)methyl]phenoxy}ethyl)-1-piperazinyl]carbonyl}-1-methyl-4(1H)-quinolinone
30472.00.602
54F2282-0139*
N-(2-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)ethyl)-1-(3-methoxyphenyl)-5-oxopyrrolidine-3-carboxamide
39292.90.578
3530625545
N-(2-fluorobenzyl)-3-{1-[4-(3-hydroxy-3-methyl-1-butyn-1-yl)benzoyl]-3-piperidinyl}propanamide
36887.20.580
78F2068-0373
N-(2-((4-(4-fluorophenyl)piperazin-1-yl)sulfonyl)ethyl)-5-oxo-1-phenylpyrrolidine-3-carboxamide
39693.80.574
2625947446
N-(3-{4-[({[5-(methoxymethyl)-2-thienyl]carbonyl}amino)methyl]-5-methyl-1,3-oxazol-2-yl}phenyl)-1-methyl-3-piperidinecarboxamide
468110.90.587
6066172782
(4-{2-[4-(2,3-dihydro-1-benzofuran-2-ylcarbonyl)-1-piperazinyl]ethoxy}benzyl)methyl(6-quinolinylmethyl)amine
452107.10.572
6978170314
methyl 5-{[3-(2-hydroxyethoxy)benzyl]amino}-1-(2-phenylethyl)-3-[(tetrahydro-2-furanylcarbonyl)amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
38891.90.529
6167801543
N-[3-(4-{[3-(4-fluorophenyl)-3-(2-furyl)propyl]amino}-1-piperidinyl)phenyl]isonicotinamide
31674.90.173
3329194995
4-phenyl-N-(3-{4-[(3-pyridinylmethyl)amino]-1-piperidinyl}phenyl)butanamide
41297.60.588

*Compounds purchased from Life Chemicals Inc (Niagara-on-the-Lake, Canada). The rest of compounds were purchased from Chembridge (San Diego, CA, USA).



The 1st-6th line of left column of Results section on page 317:

At 10 μM concentration, 13 compounds were able to prevent MERS-CoV plaques formation by 2.4-59.2% (Table 1). The strongest compound was no. 74, which produced 59.2% reduction in MERS-CoV plaques formation. Compounds 73, 22, and 76 produced 49.8%, 36.5%, and 34.6% inhibition (Fig. 3).



This Article


Cited By Articles
  • CrossRef (0)

Services
Social Network Service

e-submission

Archives